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Objective: A study was conducted to establish the bioequivalence between different 
sustained-release formulations of valproic acid (Depakene R and Selenica R), which were 
developed in Japan.
Materials and methods: The clinical investigation was designed in a randomized, cross-
over fashion with a single dose given to 12 healthy subjects. The subjects were administered a 
single 600 mg dose of valproic acid in one of two formulations. Serial venous blood samples 
were obtained over 72 hours after each administration to measure valproic acid in serum by 
enzyme immunoassay (EIA). In addition, a dissolution test was performed. Each sample was 
analyzed by an high-performance liquid chromatography to determine the dissolution rate of 
valproic acid.
Results: No difference in maximum concentration or area under the curve was found 
between the two formulations. The time to maximum concentration of the new formation was 
signiﬁ  cantly delayed compared with the conventional formulation (10.8 ± 1.7 versus 17.6 ± 
1.8 hours, p   0.001). Apparent clearance or elimination half-life did not differ between the 
two formulations. An in vitro dissolution study showed that Depakene R was signiﬁ  cantly more 
dissoluble than Selenica R.
Conclusion: Based on the results, the present study demonstrated a signiﬁ  cant difference 
between the two sustained-release formulations in the absorption proﬁ  le, and also demonstrated 
that the bioavailability of valproic acid in the two formulations was similar but absorption speed 
(lag time) was very different.
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Introduction
Successful long-term treatment of patients with epilepsy requires selection of an 
appropriate antiepileptic regimen, optimal dosing and patient compliance (Pugh and 
Garnett 1991; Buck et al 1997). Sustained-release formulations of antiepileptic drugs 
can be very helpful in achieving treatment objectives. Stable serum levels without 
marked peak-to-trough ﬂ  uctuations, reduced frequency of dosing, and the possibility 
of dosing ﬂ  exibility may all improve compliance, patient satisfaction and, ultimately, 
quality of life (Bialer 1992; Cramer et al 1995; Pellock et al 2004).
Valproic acid has been widely used in the last decade and is now considered a 
relatively safe and effective anticonvulsant agent (Perucca 2002). Recently, several 
investigations have proposed its use in the treatment of anxiety, alcoholism, and 
mood disorders (Bowden and Singh 2005; Nasrallah et al 2006). Valproic acid is 
characterized by dose-limited absorption, nonlinear plasma protein binding, and 
multiple metabolic pathways of elimination (Gugler and von Unruh 1980; Zaccara 
et al 1988; Perucca 2002). Once absorbed, valproic acid is largely bound to plasma Drug Design, Development and Therapy 2008:2 140
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proteins and has a relatively small volume of distribution. 
Its concentration in cerebral spinal ﬂ  uid is approximately 
one-tenth that in plasma and is directly correlated with the 
concentration found in tears. At therapeutic doses, valproic 
acid’s half-life varies from 10 to 20 hours in adults, while 
it is signiﬁ  cantly shorter (6 to 9 hours) in children (Zaccara 
et al 1988; Perucca 2002). Valproic acid undergoes extensive 
liver metabolism. Numerous metabolites have been positively 
identiﬁ  ed and there is reasonable evidence that several of 
them contribute to its pharmacological actions or toxicity 
(Zaccra et al 1988; Eadie 1991).
Valproic acid is available in different dosage forms for 
parenteral and oral use. All available oral formulations are 
almost completely bioavailable, but they differ in dissolution 
characteristics and absorption rates. The sustained-release 
formulation (Depakene R) can therefore be given once or 
twice daily (Doughty et al 2003; Genton 2005). The tablet 
core consists of a matrix structure that is covered with the 
sustained-released membrane. The elution of valproic acid 
is controlled as the substance passes through the core of the 
matrix structure and, further, through the sustained-released 
membrane.
Recently another sustained-release formulation containing 
200 mg valproic acid (Selenica R) has been developed and 
is available in Japan (Fujisaki et al 2006). Selenica R has 
a double-coating system that provides a mechanism that is 
different from the conventional sustained-release formulation. 
Preclinical studies with healthy volunteers showed there 
are different pharmacokinetic properties between this new 
formulation and the conventional formulation (Pers comm.; 
Nikken Chemical Co., Tokyo, Japan). However, there is 
no information available on absorption proﬁ  les of these 
two formulations when directly compared. We therefore 
compared the pharmacokinetic parameters of the two valproic 
acid formulations in healthy subjects. A comparative study 
of the dissolution proﬁ  les between the two tablets was also 
carried out.
Methods
In vitro dissolution test
A dissolution test was performed according to the procedure 
described in the JP Dissolution Test (paddle and beads 
method) (The Japanese Pharmacopeia 15th Edition, Japanese 
Ministry of Health, Labour and Welfare, http://www.mhlw.
go.jp/topics/bukyoku/iyaku/yakkyoku/dl/060407-1.pdf). The 
paddle rotation speed was maintained at 50 rpm at 37 °C. 
Release test was carried out in 900 ml of pH 6.8 phosphate 
buffer (0.05 mol/L) using a dissolution tester. Samples of 
10 ml were withdrawn at predetermined time intervals 
and replaced with the same volume of fresh buffer. Each 
sample solution was analyzed by high-performance liquid 
chromatography (HPLC) to determine the dissolution rate 
of valproic acid as described by Fujisaki and colleagues 
(2006). An AUV absorption spectrometer was used as 
the HPLC detector at a detection wavelength of 210 nm. 
The HPLC column was an Inertsil ODS stainless steel 
column with an inside diameter of 4.0 bmm and a length of 
25 cm (GL Science, Ins., Tokyo, Japan). The analysis was 
performed at 40 °C. The mobile phase was 0.02 M phosphate 
buffer (pH 3.0) and acetonitrile (60; 40, v/v).
In vivo bioequivalence study
Subjects
Twelve healthy Japanese volunteers (9 males, 3 females) were 
enrolled in this study. Their mean age ± SD and age range 
were 28.8   ±   4.8 and 23–36 years, respectively and mean 
body weight was 62.3 ± 13.1 with a range of 43–95 kg.
Study design
The study protocol was approved by the Ethics Committee 
of Hirosaki University School of Medicine. It was 
a randomized, two-treatment, two-period, crossover 
investigation with a washout phase of 4 weeks between 
the two study periods. The treatments consisted of a single 
oral 600 mg dose with 200 ml water. 600 mg of different 
sustained-release valproic acid formulations (three 200 mg 
tablets of Depakene R or Selenica R) were administered 
in a randomized crossover fashion with a washout period 
of at least 4-weeks. Six volunteers within each group were 
allocated to either of 2 different drug sequences: Depakene 
R-Selenica R and Selenica R-Depakene R. No meal was 
allowed until 4 hours after the dosing (1 pm). Fluid intake 
was also standard, and no alcohol, tea, coffee, and cola were 
allowed during the periods of conﬁ  nement. Study participants 
were asked to refrain from the use of all drugs, including 
over-the-counter medications, for at least 2 weeks before 
the ﬁ  rst administration, as well as during the entire study. 
Blood samples (5 ml each) for determination of valproic 
acid were collected into heparinized tubes just before and 
2, 4, 6, 8, 10, 12, 14, 16, 18, 24, 36, 48, 60, and 72 hours 
after the administration of valproic acid. Samples collected 
in the heparinized tubes were gently inverted several times. 
At the same time as blood sampling, blood pressure, heart 
rate, and self-reported adverse effects were monitored. Group 
assignment and the drug administration schedule were kept 
sealed until the blood samples were analyzed.Drug Design, Development and Therapy 2008:2 141
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Bioanalytical method
Serum concentrations of valproic acid were quantified 
with enzyme immunoassay (EIA). The detection limit was 
1.0 μg/ml. The inter- and intra-assay CVs for valproic acid 
were less than 5.5% for all quality control concentrations.
In vivo pharmacokinetic parameters
Pharmacokinetic parameters were determined by 
noncompartment model with WinNonlin software (Pharsight 
Co.,Cary, NC, USA). Apparent volume of distribution 
(Vd/F), absorption constant (Ka), elimination constant (Ke), 
and lag time (Tlag) were calculated as ﬁ  rst parameters. Area 
under the drug concentration-time curve (AUC), apparent 
clearance (CL/F), time to peak concentration (Tmax), peak 
concentration (Cmax), peak concentration at steady state 
(Cssmax) and minimum concentration at steady state (Cssmin) 
were estimated as second parameters.
Statistical analysis
Paired t-test was used for the comparison of the pharmaco-
kinetic parameters between the two phases, ie, Depakene 
R and Selenica R. Two-way analysis of variance was used for 
sequence effects. Two-way ANOVA was used for compari-
son of the in vitro dissolution study. Post hoc analyses were 
done using Bonferroni’s correction with paired t-test.
A p value of 0.05 or less was regarded as signifi-
cant. When the calculated 90% conﬁ  dence intervals with 
logarithmic transformation of pharmacokinetic data 
(Cmax and AUC) fell within 80%–125% for the ratio of the 
product average, we regarded the product as bioequivalent. 
SPSS 13.0J for Windows (SPSS Japan Inc., Tokyo, Japan) 
was used for these statistical analyses.
Results and discussion
In vitro drug release study
Dissolution curves are shown in Figure 1. All the Depakene 
R tablets were detectable after 3 hours, while it took 7 hours 
to detect all of the Selenica R tablets. Two-way ANOVA 
showed signiﬁ  cant difference in dissolution curves between 
the two formulations (p   0.001). Dissolved valproic acid 
concentrations for Depakene R were signiﬁ  cantly greater 
than those for Selenica R from 7 to 24 hours.
These ﬁ  ndings suggested the different mechanisms of 
sustained release between Depakene R and Selenica R, 
ie, the elution of valproic acid from Depakene R is controlled 
in such a way that the substance passes through the core 
matrix structure and further passes through the sustained-
release membrane, while Selenica R elutes through a mixed 
membrane composed of ethylcellulose and methacrylate 
copolymer-L (Fijisaki et al 2006) (Figure 2).
In vivo bioequivalence study
Serum concentration-time curves of valproic acid after a 
single oral dose of Depakene R tablets and Selenica R tablets 
are shown in Figure 3, and their pharmacokinetic parameters 
including direct (Table 1) and simulated (Table 2) single oral 
dose data are summarized. There were no severe adverse events 
during the study. Two subjects had mild sleepiness from 6 hours 
to 12 hours for both phases. No difference in blood pressure or 
heart rate was observed between the two formulations.
There were no differences in Cmax or total AUC between 
the new formulation (Selenica R) and conventional formu-
lation (Depakene R). Bioequivalence analyses showed that 
90% conﬁ  dence interval of log-transformed Cmax and total 
AUC between the two formulations were 92%–106% and 
101%–111%, respectively.
Lag time and tmax of Selenica R were signiﬁ  cantly delayed 
in comparison with those of Depakene R (7.1 ± 0.8 versus 1.7 ± 
0.6 hours, p   0.001 for lag time, 17.6 ± 1.8 versus 10.8 ± 
1.7 hours, p   0.001 for tmax). However, no difference was 
found in Ka. Other parameters, such as Vd/F, Ke, and CL, did 
not differ between the two formulations. Cssmax and Cssmin simu-
lated by single-oral pharmacokinetic parameters were 63.5 ± 
17.7 and 35.1 ± 10.4 μg/ml for Depakene R and 64.3 ± 16.0 
and 40.8 ± 13.1 μg/ml for Selenica R. Cssmin of Selenica R was 
signiﬁ  cantly higher than that of Depakene R ( p   0.05), but the 
Figure 1 Dissolution proﬁ  les of Depakene R and Selenica R. Error bars indicate 
standard errors. Open and solid circles are the data for Depakene R and Selenica R, 
respectively.
Notes: *p   0.05, **p   0.01, ***p   0.001.
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difference in ﬂ  uctuating drug concentration (Cssmax–Cssmin) did 
not differ between Selenica R and Depakene R. There were no 
sequence effects on the pharmacokinetic parameters.
The results of this study showed no differences in Cmax 
or AUC of valproic acid between new and conventional 
formulations. The 90% confidence interval of log-
transformed Cmax and total AUC between the two formulations 
fell within 80%–125%, suggesting that Selenica R is 
bioequivalent to Depakene R according to US Food and Drug 
Administration Guidance for Industry (see http://www.fda.
gov/CDER/guidance/3616fnl.htm). Therefore, it appears that 
blood concentrations that cause side effect are comparable 
between the two formulations.
However, absorption speed, such as lag time and hence 
tmax, were very different between the two formulations in 
the single oral dose study. This is supported by the in vitro 
dissolution study which demonstrated that Depakene R 
dissolved earlier than Selenica R. These ﬁ  ndings suggest that 
valproic acid dissolved from Depakene R appears earlier in 
the blood and brain than that from Selenica R.
Table 1 Pharmacokinetic parameters of valproate in healthy subjects (n = 12) after single oral doses of valproate (600 mg) in two 
sustained-release formulations calculated from direct data
Parameters Depakene R Selenica R Signiﬁ  cance
Cmax (μg/ml) 42.4 ± 10.7 40.9 ± 8.4 NS
Tmax (hr) 11.1 ± 1.3 16.0 ± 1.6 p   0.001
AUC (0–48) (hr* μg/mL) 1361 ± 346 1458 ± 342 NS
AUC (0–∞) (hr* μg/mL) 1408 ± 403 1536 ± 392 NS
Elimination half-life (hr) 12.9 ± 2.6 12.7 ± 2.9 NS
Note: Data are shown as mean ± SD for pharmacokinetic parameters.
Abbreviations: Cmax, peak concentration; tmax, time to peak concentration in serum;   AUC (0–48), are under plasma concentration-time curve (AUC) from 0 to 48 hours;   AUC 
(0–∞),   AUC from 0 to inﬁ  nity; NS, not signiﬁ  cant; SD, standard deviation.
Figure 2 Tablet characteristics for the slow-release preparations of Depakene R and Selenica R.
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On the other hand, no changes in physiological and 
mental status in our subjects were observed between 
Selenica R treatment and Depakene R treatment in this 
study. This is explained by similar exposure (AUC) and/or 
Cmax in the two formulations. Because therapeutic antiepi-
leptic effects or mood-stabilizing effects are associated with 
exposure to valproic acid, when a sustained-release prepa-
ration is switched to another formulation, inconsistencies 
in pharmacokinetic parameters, such as lag time and tmax, 
do not necessarily mean alteration in clinical response. 
This was conﬁ  rmed by our previous study (Yasui-Furukori 
et al 2007).
Conclusion
The present study demonstrated that the bioavailability of 
valproic acid in two formulations was similar but absorp-
tion time was different because of the different dissolution 
proﬁ  les.
Table 2 Estimated pharmacokinetic parameters in subjects receiving a single oral dose of valproate in two sustained-release 
formulations (n = 12)
Parameters Depakene R Selenica R Signiﬁ  cance
Vd/F (L) 9.5 ± 2.9 8.7 ± 1.9 NS
Ka (1/hr) 0.21 ± 0.08 0.17 ± 0.07 NS
Ke (1/hr) 0.056 ± 0.012 0.058 ± 0.014 NS
T lag (hr) 1.7 ± 0.6 7.2 ± 0.8 p   0.001
AUC (hr* mg/mL) 1241 ± 329 1300 ± 317 NS
CL/F (L/hr) 0.53 ± 0.17 0.49 ± 0.13 NS
Tmax (hr) 10.8 ± 1.6 17.6 ± 1.7 p   0.001
Cmax (mg/ml) 40.2 ± 10.5 39.3 ± 8.4 NS
Cssmax (mg/ml) 63.5 ± 16.9 64.3 ± 15.3 NS
Cssmin (mg/ml) 35.1 ± 10.0 40.8 ± 12.5 p   0.05
Note: Data are shown as mean ± SD for pharmacokinetic parameters.
Abbreviations:   Vd/F, apparent volume of distribution; Ka, absorption constant; Ke, elimination constant; Tlag, lag time; AUC (0–∞), AUC from 0 to inﬁ  nity; Cl/F, 
apparent total clearance; tmax, time to peak concentration in serum; Cmax, peak concentration; Cssmax, peak concentration at steady state; Cssmin, trough concentration 
at steady state.
Figure 3 Serum concentration-time curves of valproic acid after single oral doses of Depakene R and Selenica R. Error bars indicate standard errors. Open and solid circles 
are the data for Depakene R and Selenica R, respectively.
Notes: *p   0.05, **p   0.01, ***p   0.001.
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